NASDAQ:SGNT (SGNT) (SGNT) Stock Price, News & Analysis → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free SGNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$21.76▼$21.7650-Day Range N/A52-Week Range$10.55▼$21.88VolumeN/AAverage Volume607,514 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (SGNT) alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About (SGNT) Stock (NASDAQ:SGNT)Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story SGNT Stock News HeadlinesNovember 22, 2023 | msn.comFairfield man arrested in connection to Monday’s Vallejo shootingAugust 22, 2023 | investing.comNihar Info Global Ltd (NIHR)April 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 8, 2023 | thestreet.comChanging Landscape for Generic-Drug Makers Creates OpportunitiesApril 30, 2023 | msn.comTrying to find someone to take out all the caulking around my windows outside and redo, replace some cedar siding and all corners have holes from woodpeckers.April 15, 2023 | msn.comOlivia Wilde will helm a tv adaptation of A Visit from the Goon SquadApril 4, 2023 | msn.comNo One Cares About Kamala HarrisMarch 12, 2023 | msn.com'Please be patient': MBTA update on speed restrictionsApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 10, 2023 | msn.comChicago River Dyeing 2023, St. Patrick's Day Parade To Take Place This WeekendFebruary 22, 2023 | technews.tmcnet.comLatticeFlow AG Appoints Global Technology Executive, Andre Boisvert, As Chairman of The BoardJanuary 2, 2023 | thestreet.comSagent Pharmaceuticals (SGNT) Soared Today on Nichi-Iko DealDecember 3, 2022 | msn.comWC Daily Preview: USA/NED, ARG/AUS open Round of 16September 20, 2022 | investing.comSalora International Ltd (SALI)September 15, 2022 | msn.comCharacter Designs That Drastically ChangedAugust 9, 2022 | msn.comJane Seymour hails close friend Olivia Newton-John for ‘changing the world’August 8, 2022 | msn.comWhat On Earth Will A Live-Action Pac-Man Movie Look Like?July 14, 2022 | investing.comSungold Capital Ltd (SUNG)December 2, 2021 | bbc.co.ukJeane Freeman: Inside The PandemicNovember 13, 2021 | dailymail.co.ukCleo Smith: Terrified neighbour of alleged doll-obsessed kidnapper fears locals will burn down houseNovember 11, 2021 | dailymail.co.ukCleo Smith: Forensics spray substance in Carnarvon, WA as Mark McGowan shoots down $1million rewardNovember 9, 2021 | dailymail.co.ukCar of Cleo Smith's alleged abductor becomes focus of investigation as officers scour phone recordsNovember 8, 2021 | msn.comHero detective who found missing girl Cleo Smith visits family homeNovember 8, 2021 | dailymail.co.ukHero detective who led Cleo Smith's rescue visits family home ahead of a week of crucial interviewsSee More Headlines Receive SGNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (SGNT) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2015Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SGNT CUSIP78669210 CIK1369786 Webwww.sagentpharma.com Phone+1-847-9081604FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report SGNT Stock Analysis - Frequently Asked Questions How were (SGNT)'s earnings last quarter? (SGNT) (NASDAQ:SGNT) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.06. The business earned $77.30 million during the quarter, compared to analysts' expectations of $83.28 million. The business's revenue was up 11.7% on a year-over-year basis. During the same period last year, the firm posted $0.09 EPS. What other stocks do shareholders of (SGNT) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (SGNT) investors own include Mazor Robotics (MZOR), Endocyte (ECYT), Inovio Pharmaceuticals (INO), Surgery Partners (SGRY), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Chatham Lodging Trust (CLDT), CTI BioPharma (CTIC), Daré Bioscience (DARE) and Dynavax Technologies (DVAX). This page (NASDAQ:SGNT) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (SGNT) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.